We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry: Biosimilar Review Goals ‘Not Sufficiently Aggressive’
As the FDA and biosimilar makers start negotiations to develop a user fee program, several areas of disagreement are coming to light, including how to phase in performance goals for the agency.